-
EP2906212
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2906212
| EP2906212 - THERAPEUTIC COMPOUNDS AND COMPOSITIONS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 26.02.2021 Database last updated on 31.08.2024 | |
| Former | Examination is in progress Status updated on 10.04.2019 | Most recent event Tooltip | 26.02.2021 | Application deemed to be withdrawn | published on 31.03.2021 [2021/13] | Applicant(s) | For all designated states Agios Pharmaceuticals, Inc. 88 Sidney Street Cambridge, MA 02139 / US | [2016/26] |
| Former [2015/34] | For all designated states Agios Pharmaceuticals, Inc. 38 Sidney Street Cambridge, MA 02139 / US | Inventor(s) | 01 /
POPOVICI-MULLER, Janeta 12 Clarke Farm Rd. Windham, New Hampshire 03087 / US | 02 /
SALITURO, Francesco Gerald 25 Baker Drive Marlborough, Massachusetts 01752 / US | 03 /
SAUNDERS, Jeffrey Owen 188 Tower Road Lincoln, Massachusetts 01773 / US | 04 /
TRAVINS, Jeremy 59 Flagg Road Southborough, MA 01772 / US | 05 /
YAN, Shunqi 55 Stepping Stone Irvine, California 92603 / US | [2015/34] | Representative(s) | Bösl, Raphael Konrad Patentanwälte Isenbruck Bösl Hörschler PartG mbB Eastsite One Seckenheimer Landstraße 4 68163 Mannheim / DE | [N/P] |
| Former [2015/34] | Bösl, Raphael Konrad Isenbruck Bösl Hörschler LLP Patentanwälte Prinzregentenstraße 68 81675 München / DE | Application number, filing date | 13846787.3 | 11.10.2013 | [2015/34] | WO2013US64601 | Priority number, date | US201261714179P | 15.10.2012 Original published format: US 201261714179 P | [2015/34] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2014062511 | Date: | 24.04.2014 | Language: | EN | [2014/17] | Type: | A1 Application with search report | No.: | EP2906212 | Date: | 19.08.2015 | Language: | EN | The application published by WIPO in one of the EPO official languages on 24.04.2014 takes the place of the publication of the European patent application. | [2015/34] | Search report(s) | International search report - published on: | US | 24.04.2014 | (Supplementary) European search report - dispatched on: | EP | 09.05.2016 | Classification | IPC: | A61K31/17, A61K31/18, C07D213/74, C07D239/42, C07D309/14, C07D333/20, C07D409/12, C07D413/12, C07C311/44 | [2016/23] | CPC: |
A61K31/17 (EP,US);
C07C311/44 (US);
A61K31/18 (EP,US);
A61K31/351 (EP,US);
A61K31/381 (EP,US);
A61K31/397 (EP,US);
A61K31/422 (EP,US);
A61K31/4402 (EP,US);
A61K31/4406 (EP,US);
A61K31/4436 (EP,US);
A61K31/505 (EP,US);
A61K31/5377 (EP,US);
A61K31/541 (EP,US);
A61K31/553 (EP,US);
A61K45/06 (US);
A61P35/00 (EP);
A61P35/02 (EP);
A61P43/00 (EP);
C07D213/40 (EP,US);
C07D213/74 (EP,US);
C07D239/42 (EP,US);
C07D267/10 (EP,US);
C07D295/26 (EP,US);
C07D309/14 (EP,US);
|
| Former IPC [2015/34] | A61K31/17, A61K31/18 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/34] | Extension states | BA | 30.04.2015 | ME | 30.04.2015 | Title | German: | THERAPEUTISCHE VERBINDUNGEN UND ZUSAMMENSETZUNGEN | [2015/34] | English: | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | [2015/34] | French: | COMPOSÉS ET COMPOSITIONS THÉRAPEUTIQUES | [2015/34] | Entry into regional phase | 30.04.2015 | National basic fee paid | 30.04.2015 | Search fee paid | 30.04.2015 | Designation fee(s) paid | 30.04.2015 | Examination fee paid | Examination procedure | 30.04.2015 | Examination requested [2015/34] | 05.12.2016 | Amendment by applicant (claims and/or description) | 15.04.2019 | Despatch of a communication from the examining division (Time limit: M04) | 20.08.2019 | Reply to a communication from the examining division | 24.07.2020 | Despatch of a communication from the examining division (Time limit: M03) | 04.11.2020 | Application deemed to be withdrawn, date of legal effect [2021/13] | 20.11.2020 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2021/13] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 15.04.2019 | Fees paid | Renewal fee | 27.10.2015 | Renewal fee patent year 03 | 27.10.2016 | Renewal fee patent year 04 | 27.10.2017 | Renewal fee patent year 05 | 29.10.2018 | Renewal fee patent year 06 | 28.10.2019 | Renewal fee patent year 07 | Penalty fee | Additional fee for renewal fee | 31.10.2020 | 08 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]EP0022958 (BAYER AG [DE]) [X] 1-6 * examples 120, 121 *; | [A]US5807876 (ARMISTEAD DAVID M [US], et al) [A] 1-15 * the whole document *; | [X]WO9932463 (BAYER AG [US]) [X] 1-7,15 * Table 3 page 81 *; | [X]US6262113 (WIDDOWSON KATHERINE LOUISA [US], et al) [X] 1-6 * claim 1 *; | [X]US2002188027 (ROBINSON LOUISE [US], et al) [X] 1-7,15 * paragraph [0115]; claims 1, 7, 16; compounds 7-11, 17, 31-32, 34-36, 38-40, 42 *; | [A] - PATRICK S. WARD ET AL, "The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting [alpha]-Ketoglutarate to 2-Hydroxyglutarate", CANCER CELL, (20100301), vol. 17, no. 3, doi:10.1016/j.ccr.2010.01.020, ISSN 1535-6108, pages 225 - 234, XP055007472 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/j.ccr.2010.01.020 | International search | [Y]US2003109527 (JIN QI [US], et al); | [A]US2009093526 (MILLER SCOTT [US], et al); | [A]WO2011050210 (AGIOS PHARMACEUTICALS INC [US], et al); | [A]WO2012009678 (AGIOS PHARMACEUTICALS INC [US], et al); | [Y]US2012164143 (TEELING JESSICA [NL], et al); | [X] - "COM POUND SUM M ARY FOR CID 4078245", PUBCHEM CID, (20050913), Database accession no. 4078245, XP055245486 | [X] - "T5403662 | C19H14CL3N3O3S", PUBCHEM CID, (20050917), Database accession no. 4854170, XP055245489 | [A] - POPOVICI-MULLER ET AL., "Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo.", ACS MEDICINAL CHEMISTRY LETTERS, (2012), vol. 3, pages 850 - 855, XP055159509 DOI: http://dx.doi.org/10.1021/ml300225h |